Moderna Lifts 2026 Revenue Growth Outlook to 15%-25% From Up to 10%
MRNA has more than doubled off its 52-week low of $22.28 on light trading volume (0.3× avg).
Summary
Moderna raised its 2026 revenue growth outlook to 15%-25%, up from a prior cap of up to 10%, and guided to roughly 10 percentage points of gross margin expansion excluding a litigation settlement charge. The company also laid out about $4B in 2027 cash costs and roughly $9B of total liquidity at year-end 2026, which includes cash, investments and undrawn borrowing capacity rather than cash alone. It amended a $1.5B facility, pushing maturity to 2031, extending access to the remaining $900M through 2029 and cutting drawn-rate interest by 75 basis points. The raise lands after a strong stretch: Q3 delivered $162M of net income ($0.38 diluted EPS) on $1.3B of revenue, up 29%, and the stock had already repriced sharply on the August intismeran melanoma data. Formal 2027 guidance comes on the Q4 2026 earnings call, so this framework is not yet the full-year number.
At the time of this announcement, MRNA was trading at $247.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $100.6B. The 52-week trading range was $22.28 to $280.80. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.